Related Experiment Videos
First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants
Insights
Pneumococcal vaccines induced varied antibody responses in children. Antibody levels to most pneumococcal types decreased rapidly after vaccination, indicating a need for further research into vaccine efficacy.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Background:
- Pneumococcal infections pose a significant health risk to young children.
- Evaluating the immunogenicity of pneumococcal vaccines is crucial for public health.
Purpose of the Study:
- To assess the antibody responses to a 14-valent pneumococcal vaccine in infants.
- To analyze immunoglobulin class-specific responses and the durability of antibody levels.
Main Methods:
- Infants received two doses of pneumococcal vaccine or saline control at 7 and 13 months.
- Total and immunoglobulin class-specific antibodies were measured using radioimmunoassay and enzyme-linked immunosorbent assay.
Main Results:
- Types 3 and 18C showed strong responses; types 14 and 19F showed intermediate responses across all immunoglobulin classes.
- Types 6A and 23F elicited weak responses, primarily in the immunoglobulin M class.
- Antibody levels declined rapidly after both vaccine doses for most pneumococcal types.
Conclusions:
- The 14-valent pneumococcal vaccine elicited variable antibody responses in infants.
- The rapid decline in antibody levels suggests potential limitations in long-term protection.
Abstract:
Total (radioimmunoassay) and immunoglobulin class-specific (enzyme-linked immunosorbent assay) antibody responses to pneumococcal capsular polysaccharides were measured in children who received the first dose of 14-valent pneumococcal or control (saline) vaccine at the age of 7 months and the second dose at the age of 13 months. Types 3 and 18C elicited strong antibody responses and types 14 and 19F elicited intermediate responses in all immunoglobulin classes after both doses of the vaccine. The generally poor immunogen types 6A and 23F elicited a weak antibody response mainly in the immunoglobulin M class. The antibody levels to most pneumococcal types also decreased rapidly after both injections of the vaccine.